Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00845026 · ClinicalTrials.gov registry record · Phase 2
A Safety Study Comparing LY2140023 to Atypical Antipsychotic Standard Treatment in Schizophrenic Patients
A Phase 2 study, sponsored by Denovo Biopharma.
- Completed
- Registry status
- Phase 2
- Development phase
- 261
- Enrollment target
NCT00845026 is a Phase 2 study that has completed, run by Denovo Biopharma. The registered enrollment target is 261 participants.
The verdict
NCT00845026, a Phase 2 study, has completed, sponsored by Denovo Biopharma.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 261 participants
- Enrollment target
Study Summary
The primary objective of this study was to assess time to discontinuation due to lack of tolerability among patients with schizophrenia receiving LY2140023, given orally twice daily for 24 weeks, versus those on atypical antipsychotic standard-of-care (SOC) treatment. Lack of tolerability was defined as discontinuation due to adverse events (AEs). Patients who completed the active treatment phase were eligible to continue to an optional 28 weeks of treatment extension phase. This extension phase assessed key safety and efficacy measures.
Interventions
- DRUG risperidone
- DRUG olanzapine
- DRUG aripiprazole
- DRUG LY2140023
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 261 participants |
| Start Date | 2009-03 |
| Est. Completion | 2010-12 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00845026
The ClinicalTrials.gov registry entry for NCT00845026 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 261 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Denovo Biopharma, which has 10 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 4 interventions - of which risperidone is the first listed.
NCT00845026 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00845026 about?
NCT00845026 is a clinical study titled "A Safety Study Comparing LY2140023 to Atypical Antipsychotic Standard Treatment in Schizophrenic Patients". The primary objective of this study was to assess time to discontinuation due to lack of tolerability among patients with schizophrenia receiving LY2140023, given orally twice daily for 24 weeks, versus those on atypical antipsychotic standard-of-care (SOC) treatment. Lack of tolerability was define...
What is the current status of trial NCT00845026?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 261 participants. The study started on 2009-03. Estimated completion is 2010-12.
What interventions are being tested in trial NCT00845026?
The interventions under investigation include: risperidone (DRUG), olanzapine (DRUG), aripiprazole (DRUG), LY2140023 (DRUG).
Who is sponsoring clinical trial NCT00845026?
This trial is sponsored by Denovo Biopharma, which has 10 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.